Stanford University
Showing 31-40 of 61 Results
-
Joseph Shrager
Professor of Cardiothoracic Surgery
On Leave from 02/03/2025 To 05/30/2025Current Research and Scholarly InterestsIn clinical research, Dr. Shrager studies outcomes in a variety of areas within Thoracic Surgery including: parenchyma-sparing operations and minimally invasive resections for lung cancer, transcervical thymectomy for myasthenia gravis, diaphragm plication, and surgical treatment of emphysema.
Dr. Shrager's lab is focused on the impact of disease states upon the diaphragm. His group published the seminal paper (NEJM) describing diaphragm atrophy assoc'd with mechanical ventilation. -
Surbhi Sidana, MD
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
BioDr. Surbhi Sidana is an Associate Professor of Medicine at Stanford University and specializes in the treatment of multiple myeloma and related disorders. She leads the Myeloma CAR-T/Immunotherapy program at Stanford.
Dr Sidana grew up in Delhi, India, where she completed her initial medical training. She then moved to the U.S and completed her Internal Medicine Residency at Cleveland Clinic in Cleveland, Ohio, followed by Hematology/Oncology fellowship at Mayo Clinic in Rochester, MN. Following this, she completed an Advanced Hematology Fellowship in Myeloma, Amyloidosis and Related Disorders at Mayo Clinic in Rochester, MN before joining Stanford University as a faculty member in 2019, where she has led the development of the myeloma CAR-T and bispecific antibody program.
Dr Sidana has an active, broad research portfolio that includes clinical trials of novel therapies in myeloma and related disorders, translational research, epidemiologic and patient reported outcome studies. She has a special focus on research with immunotherapies such as CAR-T cell therapy and bispecific antibodies. She has published over 80 research manuscripts. Dr Sidana is the Leader of the Myeloma Disease Focused Group and the Associate Director for Clinical Research in the BMT and Cell Therapy Division at Stanford University. She also co-leads a multi-institutional collaboration on real world outcomes with immunotherapies in myeloma.
Dr Sidana is actively involved in and holds leadership positions in national and international professional societies. She co-chairs the Quality-of-Life Committee of the International Myeloma Working Group and is the Vice-Chair of the American Society of Hematology Committee on Communications. She also a member of the ASH Editor Search Committee and the SWOG Myeloma Committee. -
Arend Sidow
Professor of Pathology and of Genetics
On Leave from 04/01/2024 To 02/21/2025Current Research and Scholarly InterestsWe have a highly collaborative research program in the evolutionary genomics of cancer. We apply well-established principles of phylogenetics to cancer evolution on the basis of whole genome sequencing and functional genomics data of multiple tumor samples from the same patient. Introductions to our work and the concepts we apply are best found in the Newburger et al paper in Genome Research and the Sidow and Spies review in TIGS.
More information can be found here: http://www.sidowlab.org -
Branimir I. Sikic, M. D.
Professor of Medicine (Oncology), Emeritus
Current Research and Scholarly InterestsResearch Interests: cancer pharmacology, mechanisms of resistance to anticancer drugs, regulation and function of MDR1 and tubulin genes, CD47 as a target for activation of anticancer macrophases, Phase I trials of new drugs, gene expression profiling of cancers
-
Robert Sinclair
Charles M. Pigott Professor in the School of Engineering
BioUsing high-resolution transmission electron microscopy, Sinclair studies microelectronic, magnetic thin film microstructure and nanomaterials.
-
Eila C. Skinner
Thomas A. Stamey Research Professor of Urology
On Partial Leave from 11/16/2024 To 05/16/2025Current Research and Scholarly InterestsMy research focuses on outcomes in the treatment of muscle invasive and high-grade non-muscle invasive bladder cancer. This includes identifying markers of prognosis, predictive markers for response to surgery and chemotherapy, and working toward an individualized, multidisciplinary approach to disease management. I have also focused on optimizing the use of lower urinary tract reconstruction in patients undergoing cystectomy, and developing interventions to improve patient quality of life.
-
Stephen Skirboll
Associate Professor of Neurosurgery
Current Research and Scholarly InterestsMy research focuses on screening strategies to identify and characterize cancer stem cells (CSCs) in human gliomas. We are pursuing this in several ways: 1) a novel colony-forming antibody live cell array to identify distinct CSC surface phenotypes, 2) RNAi screens to identify kinases critical for CSC tumorigenicity, 3) high throughput small molecule and chemical screens to identify compounds that selectively kill or target CSCs, and 4) identifying CSCs using the tumor specific EGFRvIII
-
Jan Skotheim
Professor of Biology and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsMy overarching goal is to understand how cell growth triggers cell division. Linking growth to division is important because it allows cells to maintain specific size range to best perform their physiological functions. For example, red blood cells must be small enough to flow through small capillaries, whereas macrophages must be large enough to engulf pathogens. In addition to being important for normal cell and tissue physiology, the link between growth and division is misregulated in cancer.
-
Melody Smith, MD, MS
Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
BioDr. Smith is a board-certified, fellowship-trained medical oncologist and hematologist. She is an assistant professor in the Department of Medicine in the Division of Blood & Marrow Transplantation and Cellular Therapy.
She is also a physician-scientist who conducts extensive research. As a medical student, she completed a fellowship at the National Institutes of Health (NIH) in the Clinical Research Training (now, the Medical Research Scholars) Program. Subsequently, following her clinical fellowship, she was a post-doctoral researcher at Memorial Sloan Kettering Cancer Center. The research in her lab focuses on investigations of the biology of chimeric antigen receptor (CAR) T cells to improve the efficacy and safety of this therapy (1) by investigating donor (Nature Medicine, 2017) and off-the-shelf CAR T cells in mouse models and (2) by assessing mechanisms for the impact of the intestinal microbiome on CAR T cell response (Nature Medicine, 2022).
Dr. Smith presents the findings of her research at regional, national, and international conferences. Further, she has co-authored articles on topics within the field of cancer immunology, including cancer immunotherapy, stem cell transplantation, and CAR T cell therapy. Her work has appeared in journals, among others Nature, Nature Immunology, Nature Medicine, Blood, and Transplantation and Cellular Therapy. She serves a peer reviewer for publications in journals, such as NEJM Evidence, Science Advances, Blood, Cancer Cell, and Molecular Therapy. She also has contributed to chapters in books, including Pocket Oncology, Current Concepts and Controversies in Hematopoietic Cell Transplantation, and Advanced Concepts in Human Immunology: Prospects for Disease Control.
She has earned numerous honors; the American Society of Hematology (ASH), the Society for Immunotherapy of Cancer, the European Society for Blood and Marrow Transplantation, and several other professional organizations have recognized her achievements as a clinician, researcher, and scholar.
Dr. Smith is a member of the ASH Committee on Emerging Gene and Cell Therapies and the ASH Committee on Diversity, Equity & Inclusion. Additionally, she serves on committees within the institution and professional organizations focused on promoting diversity among hematology and cell therapy specialists. -
Michael Snyder, Ph.D.
Stanford W. Ascherman Professor of Genetics
On Partial Leave from 12/02/2024 To 12/01/2025Current Research and Scholarly InterestsOur laboratory use different omics approaches to study a) regulatory networks, b) intra- and inter-species variation which differs primarily at the level of regulatory information c) human health and disease. For the later we have established integrated Personal Omics Profiling (iPOP), an analysis that combines longitudinal analyses of genomic, transcriptomic, proteomic, metabolomic, DNA methylation, microbiome and autoantibody profiles to monitor healthy and disease states